Mallia Therapeutics and Northway Biotech Partner for Hair Loss Treatment Production

Mallia Therapeutics and Northway Biotech have announced a strategic collaboration to manufacture Mallia's soluble CD83 protein (sCD83), a promising treatment for hair loss. This partnership aims to facilitate the scale-up production of sCD83 using the Pichia pastoris expression system, focusing on hair follicle formation and growth.

The agreement will see Northway Biotech leveraging its biologics manufacturing expertise, developing analytical methods, and ensuring the production of a cGMP drug substance. The project is poised to tackle both androgenetic alopecia and alopecia areata, promising potential new therapeutic approaches.

Leadership from both companies expresses confidence in the venture. Mallia's Dr. Manfred Groeppel highlights the project's significance for patients, while Northway's Prof. Vladas Algirdas Bumelis stresses adherence to top manufacturing standards. The collaboration is aimed at entering the lucrative alopecia market with a safe topical solution.